These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 498418)
21. Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy. Gessner T; Preisler HD; Azarnia N; Bolanowska W; Vogler WR; Grunwald H; Joyce R; Goldberg J Med Oncol Tumor Pharmacother; 1987; 4(1):23-31. PubMed ID: 3600054 [TBL] [Abstract][Full Text] [Related]
22. Body residue and metabolism of adriamycin and daunorubicin in control and phenobarbital-pretreated mice. Bolanowska W; Gessner T Xenobiotica; 1982 Feb; 12(2):125-36. PubMed ID: 7090422 [TBL] [Abstract][Full Text] [Related]
23. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients. Eksborg S; Ehrsson H; Andersson B; Beran M J Chromatogr; 1978 Jun; 153(1):211-8. PubMed ID: 659557 [TBL] [Abstract][Full Text] [Related]
24. Microbiol N-acetylation of daunorubicin and daunorubicinol. Hamilton BK; Sutphin MS; Thomas MC; Wareheim DA; Aszalos AA J Antibiot (Tokyo); 1977 May; 30(5):425-6. PubMed ID: 407204 [No Abstract] [Full Text] [Related]
25. High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin. Albrecht KW; de Witt Hamer PC; Leenstra S; Bakker PJ; Beijnen JH; Troost D; Kaaijk P; Bosch AD J Neurooncol; 2001 Jul; 53(3):267-71. PubMed ID: 11718259 [TBL] [Abstract][Full Text] [Related]
26. Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia. Paul C; Baurain R; Gahrton G; Peterson C Cancer Lett; 1980 Jun; 9(4):263-9. PubMed ID: 6930988 [TBL] [Abstract][Full Text] [Related]
27. Uptake and metabolism of daunorubicin by human leukemia cells. DeGregorio MW; Carrera CJ; Klock JC; Wilbur JR Cancer Chemother Pharmacol; 1982 Dec; 10(1):29-32. PubMed ID: 6961971 [TBL] [Abstract][Full Text] [Related]
28. Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells. Determination by high pressure liquid chromatography. Londos-Gagliardi D; Baurain R; Robert J; Aubel-Sadron G Cancer Chemother Pharmacol; 1982; 9(1):45-8. PubMed ID: 6958392 [TBL] [Abstract][Full Text] [Related]
29. Microbial reduction of the side-chain carbonyl of daunorubicin and N-acetyldaunorubicin. Aszalos AA; Bachur NR; Hamilton BK; Langlykke AF; Roller PP; Sheikh MY; Sutphin MS; Thomas MC; Wareheim DA; Wright LH J Antibiot (Tokyo); 1977 Jan; 30(1):50-8. PubMed ID: 838632 [TBL] [Abstract][Full Text] [Related]
30. Distribution of daunorubicin intravenously injected or intravenously infused as free drug and as a complex with DNA in rabbits. Hulhoven R; Harvengt C Pharmacology; 1982; 24(4):253-60. PubMed ID: 7089047 [TBL] [Abstract][Full Text] [Related]
31. Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer. Ingle JN; Ahmann DL; O'Fallon JR; Bisel HF; Rubin J; Kvols LK; Giuliani ER Cancer Treat Rep; 1979; 63(11-12):1701-5. PubMed ID: 526908 [TBL] [Abstract][Full Text] [Related]
32. Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine. Charlier HA; Olson RD; Thornock CM; Mercer WK; Olson DR; Broyles TS; Muhlestein DJ; Larson CL; Cusack BJ; Shadle SE Mol Pharmacol; 2005 May; 67(5):1505-12. PubMed ID: 15705743 [TBL] [Abstract][Full Text] [Related]
33. Uptake and distribution of daunorubicin and daunorubicin-DNA complex in mice as studied by whole-body autoradiography and liquid chromatography. Andersson B; Beran M; Eberhardsson B; Eksborg S; Slanina P Cancer Chemother Pharmacol; 1979; 2(3):159-67. PubMed ID: 110487 [TBL] [Abstract][Full Text] [Related]
34. Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors. Broggini M; Italia C; Colombo T; Marmonti L; Donelli MG Cancer Treat Rep; 1984 May; 68(5):739-47. PubMed ID: 6586294 [TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Callies S; de Alwis DP; Mehta A; Burgess M; Aarons L Cancer Chemother Pharmacol; 2004 Jul; 54(1):39-48. PubMed ID: 15045528 [TBL] [Abstract][Full Text] [Related]